Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTX 471

Next Previous
Drug Profile

CTX 471

Alternative Names: CTX-471

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adimab
  • Developer Compass Therapeutics; Merck & Co
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Solid tumours

Most Recent Events

  • 16 Jun 2026 Phase-I/II clinical trials in Glioblastoma (Recurrent, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT07392957)
  • 05 May 2026 Compass Therapeutics plans a phase II trial in Solid tumours (IV) in the third quarter of 2026
  • 06 Feb 2026 Washington University School of Medicine plans a phase I/II trial for Glioblastoma (Monotherapy, Combination therapy, Second-line therapy or greater, Late stage disease) in USA in March 2026 (IV)(NCT07392957)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top